Nuveen Asset Management LLC Has $54.15 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Nuveen Asset Management LLC lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,798,989 shares of the biopharmaceutical company’s stock after selling 232,335 shares during the period. Nuveen Asset Management LLC owned approximately 1.16% of TG Therapeutics worth $54,150,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of TG Therapeutics by 3.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 92,683 shares of the biopharmaceutical company’s stock valued at $2,808,000 after purchasing an additional 2,890 shares during the period. Integral Health Asset Management LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $4,515,000. Deutsche Bank AG raised its holdings in shares of TG Therapeutics by 40.4% during the fourth quarter. Deutsche Bank AG now owns 147,020 shares of the biopharmaceutical company’s stock valued at $4,425,000 after purchasing an additional 42,272 shares during the period. Cornerstone Select Advisors LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $1,904,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $453,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Up 2.3%

TGTX opened at $34.36 on Monday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The firm has a market capitalization of $5.45 billion, a PE ratio of -343.57 and a beta of 2.21. The company’s 50-day moving average is $38.59 and its 200 day moving average is $34.03.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue was up 90.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.07) EPS. As a group, research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TGTX has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.